Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

26 Applying Pharmacogenomics in Therapeutics
39. Abraham, N.S., et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the
concomitant use of proton pump inhibitors and thienopyridines: A focused update of
the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal
risks of antiplatelet therapy and NSAID use: A report of the American College
of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation,
2010; 122(24): 2619–33.
40. Rueckert, S., et al. A monoclonal antibody as an effective therapeutic agent in breast
cancer: Trastuzumab. Expert Opin Biol Ther, 2005; 5(6): 853–66.
41. Hudis, C.A. Trastuzumab—Mechanism of action and use in clinical practice. N Engl
J Med, 2007; 357(1): 39–51.
42. Shih, C., et al. Transforming genes of carcinomas and neuroblastomas introduced into
mouse fibroblasts. Nature, 1981; 290(5803): 261–4.
43. Slamon, D.J., et al. Human breast cancer: Correlation of relapse and survival with
amplification of the HER-2/neu oncogene. Science, 1987; 235(4785): 177–82.
44. Slamon, D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 344(11):
783–92.
45. Romond, E.H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-
positive breast cancer. N Engl J Med, 2005; 353(16): 1673–84.
46. Marty, M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab
combined with docetaxel in patients with human epidermal growth factor receptor
2-positive metastatic breast cancer administered as first-line treatment: The M77001
study group. J Clin Oncol, 2005; 23(19): 4265–74.
47. Piccart-Gebhart, M.J., et al. Trastuzumab after adjuvant chemotherapy in HER2-
positive breast cancer. N Engl J Med, 2005; 353(16): 1659–72.
48. Chang, H.R. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive
breast cancer. Cancer, 2005; 116(12): 2856–67.
49. Gianni, L., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant
trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-
positive locally advanced breast cancer (the NOAH trial): A randomised controlled
superiority trial with a parallel HER2-negative cohort. Lancet, 2010; 375(9712):
377–84.
50. Untch, M., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast
cancer: Results from the GeparQuattro study. J Clin Oncol, 2010; 28(12): 2024–31.
51. Larson, J.S., et al. Analytical validation of a highly quantitative, sensitive, accurate, and
reproducible assay (HERmark) for the measurement of HER2 total protein and HER2
homodimers in FFPE breast cancer tumor specimens. Patholog Res Int, 2010; 2010:
814176.
52. Carlson, R.W., et al. HER2 testing in breast cancer: NCCN Task Force report and
recommendations. J Natl Compr Canc Netw, 2006; 4(Suppl 3): S1–22; quiz S23–4.
53. Wolff, A.C., et al. Recommendations for human epidermal growth factor receptor
2 testing in breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline update. J Clin Oncol, 2013; 31(31):
3997–4013.
54. Hernandez, J.E., et al. Clinical risk factors for hypersensitivity reactions to abacavir:
Retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials.
Programs and abstracts of the 43rd Interscience Conference on Antimicrobial Agents
and Chemotherapy, 2003; 339, September 14–17, 2003; Chicago, Illinois.
55. Hetherington, S., et al. Hypersensitivity reactions during therapy with the nucleoside
reverse transcriptase inhibitor abacavir. Clin Ther, 2001; 23: 1603–14.
56. Hughes, C.A., et al. Abacavir hypersensitivity reaction: An update. Ann Pharmacother,
2008; 42: 387–96.